172 related articles for article (PubMed ID: 19888802)
41. Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity.
Niimi K; Monk BC; Hirai A; Hatakenaka K; Umeyama T; Lamping E; Maki K; Tanabe K; Kamimura T; Ikeda F; Uehara Y; Kano R; Hasegawa A; Cannon RD; Niimi M
J Antimicrob Chemother; 2010 May; 65(5):842-52. PubMed ID: 20233776
[TBL] [Abstract][Full Text] [Related]
42. Pga26 mediates filamentation and biofilm formation and is required for virulence in Candida albicans.
Laforet L; Moreno I; Sánchez-Fresneda R; Martínez-Esparza M; Martínez JP; Argüelles JC; de Groot PW; Valentín-Gomez E
FEMS Yeast Res; 2011 Aug; 11(5):389-97. PubMed ID: 21439008
[TBL] [Abstract][Full Text] [Related]
43. Micafungin alters the expression of genes related to cell wall integrity in Candida albicans biofilms.
Kaneko Y; Ohno H; Kohno S; Miyazaki Y
Jpn J Infect Dis; 2010 Sep; 63(5):355-7. PubMed ID: 20859005
[TBL] [Abstract][Full Text] [Related]
44. Glutathione protects Candida albicans against horseradish volatile oil.
Bertóti R; Vasas G; Gonda S; Nguyen NM; Szőke É; Jakab Á; Pócsi I; Emri T
J Basic Microbiol; 2016 Oct; 56(10):1071-1079. PubMed ID: 27272511
[TBL] [Abstract][Full Text] [Related]
45. Induction of a high affinity fibronectin receptor in Candida albicans by caspofungin: requirements for beta (1,6) glucans and the developmental regulator Hbr1p.
Pendrak ML; Rodrigues RG; Roberts DD
Med Mycol; 2007 Mar; 45(2):157-68. PubMed ID: 17365652
[TBL] [Abstract][Full Text] [Related]
46. Difference in killing activity of caspofungin and paradoxical growth between Candida albicans and C. krusei clinical isolates in different media.
Varga I; Sóczó G; Kardos G; Kemény-Beke A; Kelentey B; Márton I; Majoros L
J Chemother; 2009 Feb; 21(1):36-41. PubMed ID: 19297270
[TBL] [Abstract][Full Text] [Related]
47. Exposure of Aspergillus fumigatus to caspofungin results in the release, and de novo biosynthesis, of gliotoxin.
Eshwika A; Kelly J; Fallon JP; Kavanagh K
Med Mycol; 2013 Feb; 51(2):121-7. PubMed ID: 23323804
[TBL] [Abstract][Full Text] [Related]
48. Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways.
Wiederhold NP; Kontoyiannis DP; Prince RA; Lewis RE
Antimicrob Agents Chemother; 2005 Dec; 49(12):5146-8. PubMed ID: 16304189
[TBL] [Abstract][Full Text] [Related]
49. The cell wall protein Rhd3/Pga29 is over-expressed in Candida albicans upon micafungin treatment.
Vavala E; Mignogna G; Spano F; Stringaro A; Colone M; Sanguinetti M; Maras B; Angiolella L
J Chemother; 2013 Dec; 25(6):332-40. PubMed ID: 24090751
[TBL] [Abstract][Full Text] [Related]
50. Nanoscale analysis of caspofungin-induced cell surface remodelling in Candida albicans.
El-Kirat-Chatel S; Beaussart A; Alsteens D; Jackson DN; Lipke PN; Dufrêne YF
Nanoscale; 2013 Feb; 5(3):1105-15. PubMed ID: 23262781
[TBL] [Abstract][Full Text] [Related]
51. Caspofungin kills Candida albicans by causing both cellular apoptosis and necrosis.
Hao B; Cheng S; Clancy CJ; Nguyen MH
Antimicrob Agents Chemother; 2013 Jan; 57(1):326-32. PubMed ID: 23114781
[TBL] [Abstract][Full Text] [Related]
52. The echinocandins.
Cappelletty D; Eiselstein-McKitrick K
Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
[TBL] [Abstract][Full Text] [Related]
53. In vitro activity of antifungal combinations against Candida albicans biofilms.
Tobudic S; Kratzer C; Lassnigg A; Graninger W; Presterl E
J Antimicrob Chemother; 2010 Feb; 65(2):271-4. PubMed ID: 19996142
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of the Sensititre Yeast One microdilution method for susceptibility testing of Candida species to anidulafungin, caspofungin, and micafungin.
García-Agudo L; García-Martos P; Martos-Cañadas J; Aznar-Marín P; Marín-Casanova P; Rodríguez-Iglesias M
Rev Esp Quimioter; 2012 Dec; 25(4):256-60. PubMed ID: 23303256
[TBL] [Abstract][Full Text] [Related]
55. Transcriptional regulation of the caspofungin-induced cell wall damage response in Candida albicans.
Heredia MY; Gunasekaran D; Ikeh MAC; Nobile CJ; Rauceo JM
Curr Genet; 2020 Dec; 66(6):1059-1068. PubMed ID: 32876716
[TBL] [Abstract][Full Text] [Related]
56. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
57. Non-canonical Activities of Hog1 Control Sensitivity of
Morales-Menchén A; Navarro-García F; Guirao-Abad JP; Román E; Prieto D; Coman IV; Pla J; Alonso-Monge R
Front Cell Infect Microbiol; 2018; 8():135. PubMed ID: 29774204
[TBL] [Abstract][Full Text] [Related]
58. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
Ghannoum MA; Chen A; Buhari M; Chandra J; Mukherjee PK; Baxa D; Golembieski A; Vazquez JA
Clin Microbiol Infect; 2009 Mar; 15(3):274-9. PubMed ID: 19210699
[TBL] [Abstract][Full Text] [Related]
59. The echinocandin caspofungin impairs the innate immune mechanism against Candida parapsilosis.
van Asbeck EC; Hoepelman AI; Scharringa J; Verhoef J
Int J Antimicrob Agents; 2009 Jan; 33(1):21-6. PubMed ID: 18774697
[TBL] [Abstract][Full Text] [Related]
60. Deletions of the endocytic components VPS28 and VPS32 in Candida albicans lead to echinocandin and azole hypersensitivity.
Cornet M; Gaillardin C; Richard ML
Antimicrob Agents Chemother; 2006 Oct; 50(10):3492-5. PubMed ID: 17005841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
